论文部分内容阅读
目的:观察益气养阴抑瘤方联合多西紫杉醇与顺铂治疗非小细胞肺癌的临床疗效。方法:将80例非小细胞肺癌患者随机分成对照组和治疗组各40例,对照组予TP方案化疗:第1天予多西紫杉醇(泰索帝)75mg/m2静脉滴注,第1～3天予顺铂25mg/m2静脉滴注,治疗组在对照组的基础上予内服益气养阴抑瘤方,21天为1个周期,3周期后对临床疗效、临床症候疗效、不良反应及生活质量进行评估。结果:治疗组和对照组的有效率分别为57.5%,42.5%,两组比较差异有统计学意义(P<0.05);治疗组临床症候总改善率为92.5%,对照组为62.5%,治疗组明显优于对照组(P<0.05);治疗组白细胞减少及恶心呕吐的发生率明显低于对照组(P<0.05);KPS评分提高者治疗组22例(55%),对照组15例(37.5%),治疗组明显优于对照组(P<0.05)。结论:TP方案联合益气养阴抑瘤方治疗NSCLC可在一定程度上提高疗效、缓解症状、改善生活质量、减轻化疗不良反应。
Objective: To observe the clinical efficacy of Yiqi Yangyinariowan combined with docetaxel and cisplatin in the treatment of non-small cell lung cancer. Methods: Eighty non-small cell lung cancer patients were randomly divided into control group and treatment group, 40 cases in each group. The control group received TP chemotherapy: on day 1, docetaxel (Taxotere) 3 days to cisplatin 25mg / m2 intravenous drip, the treatment group in the control group based on the internal Qi and Yin Yiliu Fang, 21 days for a period of 3 cycles after the clinical efficacy, clinical symptoms, adverse reactions And quality of life. Results: The effective rates of the treatment group and the control group were 57.5% and 42.5%, respectively, with significant difference between the two groups (P <0.05). The overall clinical symptom improvement rate was 92.5% in the treatment group and 62.5% in the control group (P <0.05). The incidence of leukopenia and nausea and vomiting in the treatment group was significantly lower than that in the control group (P <0.05). In the treatment group with KPS score improvement, 22 cases (55%) and the control group (37.5%), the treatment group was significantly better than the control group (P <0.05). Conclusion: The combination of TP and NSCLC can improve the curative effect, alleviate the symptoms, improve the quality of life and reduce the adverse reactions of chemotherapy.